Use of Letermovir as Secondary Prophylaxis in Cardiac Transplant Patient, Mismatch for CMV (d plus /r-), Resistant to Ganciclovir and Foscarnet

被引:0
|
作者
Sangani, A. [1 ]
Campanini, G. [2 ]
Puci, F. [1 ]
Truffelli, F. [1 ]
Lerta, S. [1 ]
Bruno, R. [3 ]
Seminari, E. [1 ]
机构
[1] Fdn IRCSS Policlin San Matteo, Div Infect Dis 1, Pavia, Italy
[2] Fdn IRCSS Policlin San Matteo, Microbiol & Virol Unit, Pavia, Italy
[3] Univ Pavia, Dept Med Surg Diagnost & Pediat Sci, Pavia, Italy
来源
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
968
引用
收藏
页码:S454 / S454
页数:1
相关论文
共 50 条
  • [21] Effectiveness of CMV prophylaxis in donor positive recipient negative (D+/R-) liver transplant recipients.
    Alajmi, MA
    Gregor, JC
    Marotta, PJ
    GASTROENTEROLOGY, 2000, 118 (04) : A982 - A982
  • [22] Indefinite Valganciclovir Prophylaxis among CMV D+/R- Lung Transplant Patients Is Limited by Breakthrough CMV Infections, Toxicity and Resistance
    Clancy, C.
    Shields, R.
    Toyoda, Y.
    Bhama, J.
    Kwak, E.
    Silveira, F.
    Pilewski, J.
    Crespo, M.
    Nguyen, H.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (04): : S61 - S62
  • [23] Favorable Long-Term Outcome of Late-Onset CMV Disease in D plus R- Kidney Transplant Recipients Treated With Universal Prophylaxis
    Kaminski, H.
    Couzi, L.
    Garrigue, I.
    Dechanet-Merville, J.
    Merville, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [24] FAVORABLE LONG-TERM OUTCOME OF LATE-ONSET CMV DISEASE IN D plus R- KIDNEY TRANSPLANT RECIPIENTS TREATED WITH UNIVERSAL PROPHYLAXIS
    Kaminski, Hannah
    Couzi, Lionel
    Garrigue, Isabelle
    Dechanet-Merville, Julie
    Pierre, Merville
    TRANSPLANT INTERNATIONAL, 2015, 28 : 155 - 155
  • [25] PROSPECTIVE LONG-TERM STUDY ON PRIMARY CMV INFECTIONS IN ADULT LIVER TRANSPLANT RISK PATIENTS (D plus /R-) RECEIVING VALGANCICLOVIR PROPHYLAXIS
    Makisalo, Heikki
    Hockerstedt, Krister
    Loginov, Raisa
    Lautenschlager, Irmeli
    TRANSPLANT INTERNATIONAL, 2013, 26 : 228 - 228
  • [26] CMV prophylaxis in high-risk renal transplant patients (D+/R-) by acyclovir with or without hyperimmune (CMV) immunoglobulins: A prospective study
    Rostaing, L
    Martinet, O
    Cisterne, JM
    Icart, J
    Chabannier, MH
    Durand, D
    AMERICAN JOURNAL OF NEPHROLOGY, 1997, 17 (06) : 489 - 494
  • [27] REAPPRAISAL OF ANTI-THYMOCYTE GLOBULIN INDUCTION DURING CMV INFECTION: THE RISK IS INCREASED IN R plus BUT NOT IN D plus R- KIDNEY TRANSPLANT RECIPIENTS
    Kaminski, H.
    Jarque, Marta
    Halfon, Matthieu
    Taton, Benjamin
    Di Ascia, Ludovic
    Pfirmann, Pierre
    Couzi, Lionel
    Visentin, Jonathan
    Garrigue, Isabelle
    Dechanet-Merville, Julie
    Moreau, Jean-Francois
    Crespo, Elena
    Montero, Nuria
    Melilli, Edoardo
    Meneghini, Maria
    Pascual, Manuel
    Manuel, Oriol
    Bestard, Oriol
    Merville, Pierre
    TRANSPLANT INTERNATIONAL, 2019, 32 : 23 - 23
  • [28] Ganciclovir-Resistant (GCV-R) CMV Is Common among Lung Transplant Recipients (LTR) Receiving Alemtuzumab Induction and Valganciclovir Prophylaxis (VGC px), and Treatment with Foscarnet (FOS) Is Both Ineffective and Toxic
    Minces, L.
    Clancy, C. J.
    Shields, R. K.
    Kwak, E. J.
    Silveira, F.
    Toyoda, Y.
    Bermudez, C.
    Pilewski, J.
    Crespo, M.
    Nguyen, M. H.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (04): : S142 - S142
  • [29] Real world effectiveness and feasibility of pharmacist-led preemptive CMV treatment in high risk (CMV D plus R-) liver transplant
    Revollo, Jane Y.
    Gajurel, Kiran
    Noell, Bennett C.
    Cooper, Kevin T.
    Hames, Heather
    Aldag, Erika
    Russo, Mark W.
    Casingal, Vincent P.
    JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, 2023, 6 (10): : 1097 - 1102
  • [30] Transplantation Tolerance Prevents CMV Reactivation and Preserves Kidney Allograft Function in a D plus /R- Transplant Setting.
    Dangi, A.
    Wang, J-J
    Burnette, M.
    Zhang, Z.
    Luo, X.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 398 - 399